Compare Novo Nordisk A/S (NVO) vs State Street SPDR S&P Homebuilders ETF (XHB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Novo Nordisk A/S vs State Street SPDR S&P Homebuilders ETF — how do they compare? Novo Nordisk A/S trades at $49.35 (market cap $220.53B), while State Street SPDR S&P Homebuilders ETF trades at $105.91. The key difference: Novo Nordisk A/S pays a 3.63% dividend while State Street SPDR S&P Homebuilders ETF pays none. Which is the better fit depends on your goals.
| NVO | XHB | |
|---|---|---|
Market Cap | $220.53B | — |
Sector | Health | Broad Market / Factor |
52-Week High | $71.70 | $121.36 |
52-Week Low | $35.29 | $94.86 |
Enterprise Value | $239.49B | — |
Dividend Yield | 3.63% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Novo Nordisk (NVO) trades at $49.38, down 1.87% amid legal action against Eli Lilly over GLP-1 drug advertising. The stock maintains strong fundamentals with a P/E of 11.91 and robust profitability margins (net income margin 37.2%, ROE 71.4%). Recent quarterly earnings consistently beat expectations, with Q1 2026 EPS of $1.04 surpassing the $0.87 estimate. Technical indicators show a bullish moving average signal while oscillators remain neutral, with key support at $48.
Outlook remains positive given strong earnings momentum and market leadership in GLP-1 drugs, though legal risks and competitive pressures from Eli Lilly pose near-term headwinds. Analyst consensus is bullish (57.9% buy ratings) with projected revenue growth to $327.8B in 2026. Key risks include litigation outcomes and market share competition in the weight-loss drug segment.
XHB trades at $106.07, down 2.01% over the past day amid a bearish technical signal. The ETF faces mixed housing data, with June home sales declining but new legislation potentially boosting homebuilding. Technical indicators show resistance near $108 and support at $105, while oscillators remain neutral. Recent news highlights affordability challenges from high mortgage rates and record prices, yet some sentiment improvement exists.
Outlook hinges on housing market dynamics and interest rate trends. Opportunities include potential gains from the new housing law, but risks involve persistent sales weakness and economic sensitivity. Investors should weigh legislative tailwinds against macroeconomic headwinds for directional bias.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Novo Nordisk A/S
With almost 50% market share by volume of the global insulin market, Novo Nordisk is the leading provider of diabetes-care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments, and oral antidiabetic agents. Novo also has a biopharmaceutical segment (constituting roughly 15% of revenue) that specializes in protein therapies for hemophilia and other disorders.
Read more on NVO →About State Street SPDR S&P Homebuilders ETF
XHB invests in the U.S. homebuilding industry and related sectors. It provides equal-weighted exposure to homebuilders, building products, and home improvement retailers like Home Depot, Lowe's, and Builders FirstSource.
Read more on XHB →
